SAVA - Cassava Sciences reports positive simufilam data with SavaDx in mid-stage Alzheimer's study

Cassava Sciences (SAVA) perks up 4% premarket after announcing positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease ((AD)) with a simple blood test.In this Phase 2b trial, simufilam significantly reduced plasma levels of altered filamin A in Alzheimer’s patients treated for 28 days. Plasma levels of p-tau181 also dropped significantly in these same patients. Simufilam 100 mg and 50 mg reduced plasma levels of altered filamin A by 48% (p=0.003) and 44% (p=0.02) respectively, versus placebo.Additionally, simufilam 100 mg and 50 mg reduced plasma levels of p-tau181 by 17% (p=0.01) and 15% (p=0.02) respectively, versus placebo.Plasma p-tau181 is a biomarker that is known to be elevated in Alzheimer’s disease.The company will show a poster presentation today at the AAIC in Denver, CO.

For further details see:

Cassava Sciences reports positive simufilam data with SavaDx in mid-stage Alzheimer’s study